Brilinta Tablet
NDC Package 0186-0777-08

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Brilinta (ticagrelor) tablets is ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with heart problems (such as unstable angina, previous heart attack). This formulation utilizes a tablet delivery system. Marketed by Astrazeneca Pharmaceuticals Lp, this product is identified by NDC 0186-0777 and is authorized under FDA application NDA022433.

Identification & Billing

NDC Package Code
0186-0777-08
Package Description
8 TABLET in 1 BOTTLE
Product Code
0186-0777
11-Digit Billing Format
00186077708
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Brilinta
Non-Proprietary Name
Ticagrelor
Substance Name
Ticagrelor
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
TICAGRELOR 90 mg/1
Pharmacologic Class
Usage Information
Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with heart problems (such as unstable angina, previous heart attack). It may also prevent blood clots after certain heart surgeries (such as stent placement). Ticagrelor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It keeps blood flowing smoothly in your body.

Regulatory & Marketing

Labeler Name
Astrazeneca Pharmaceuticals Lp
Product Type
Human Prescription Drug
FDA Application #
NDA022433
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-05-2011
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0186-0777). Click a package code to view its specific billing and regulatory data.

0186-0777-18
180 TABLET in 1 BOTTLE
0186-0777-28
14 TABLET in 1 BOTTLE
0186-0777-39
10 BLISTER PACK in 1 BOX, UNIT-DOSE / 10 TABLET in 1 BLISTER PACK
0186-0777-60
60 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0186-0777-08 identifies a specific commercial package of 8 tablet in 1 bottle of Brilinta, a human prescription drug labeled by Astrazeneca Pharmaceuticals Lp. This tablet is formulated for oral use and contains ticagrelor as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Astrazeneca Pharmaceuticals Lp on August 05, 2011. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with heart problems (such as unstable angina, previous heart attack). It may also prevent blood clots after certain heart surgeries (such as stent placement). Ticagrelor works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It keeps blood flowing smoothly in your body.

How is this Astrazeneca Pharmaceuticals Lp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00186077708. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0186-0777-08
11-Digit CMS (5-4-2)
00186-0777-08

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.